Literature DB >> 22904182

Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis.

Scott D Sagel1, Brandie D Wagner, Margaret M Anthony, Peggy Emmett, Edith T Zemanick.   

Abstract

RATIONALE: Progressive lung function decline is a defining feature of cystic fibrosis (CF). Because airway inflammation plays a central role in CF lung disease, inflammatory biomarkers that can be used to monitor disease activity would be valuable.
OBJECTIVES: Examine longitudinal relationships between sputum biomarkers and lung function.
METHODS: In this prospective, longitudinal cohort study, sputum induction was performed annually over 3 years in 35 children with CF. Sputum was assayed for mediators related to proteolysis and a panel of inflammatory cytokines.
MEASUREMENTS AND MAIN RESULTS: Sputum neutrophil elastase, tissue inhibitor of metalloproteinase-1, and TNF-α increased over time, whereas neutrophil elastase antiprotease complexes (NEAPCs) and secretory leukoprotease inhibitor (SLPI) significantly decreased over time. Higher detectable baseline neutrophil elastase was associated with more rapid lung function decline. Similar results for neutrophil elastase were observed in a validation cohort. When categorizing subjects as "rapid" or "slow" decliners, logistic regression demonstrated that the initial measurement of neutrophil elastase had the highest individual predictive value for subsequent lung function decline, whereas neutrophil elastase, IL-8, and IL-6 had the highest combined predictive value. Lung function decline was associated with increases in neutrophil counts, neutrophil elastase, and IL-1β and declines in NEAPCs and SLPI.
CONCLUSIONS: In children with CF, a single determination of sputum biomarkers, particularly neutrophil elastase, has predictive value for subsequent lung function decline, and longitudinal changes in sputum inflammatory biomarkers are related to lung function changes. Based on our results, sputum neutrophil elastase was the most informative biomarker to monitor disease activity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22904182      PMCID: PMC3530222          DOI: 10.1164/rccm.201203-0507OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  34 in total

1.  Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis.

Authors:  S Lorraine Martin; Damian Downey; Diana Bilton; Mary T Keogan; Julia Edgar; J Stuart Elborn
Journal:  Pediatr Pulmonol       Date:  2006-02

2.  Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis.

Authors:  Michael W Konstan; Wayne J Morgan; Steven M Butler; David J Pasta; Marcia L Craib; Stefanie J Silva; Dennis C Stokes; Mary Ellen B Wohl; Jeffrey S Wagener; Warren E Regelmann; Charles A Johnson
Journal:  J Pediatr       Date:  2007-06-22       Impact factor: 4.406

3.  alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients.

Authors:  M Griese; P Latzin; M Kappler; K Weckerle; T Heinzlmaier; T Bernhardt; D Hartl
Journal:  Eur Respir J       Date:  2006-10-18       Impact factor: 16.671

4.  Aerosol alpha 1-antitrypsin treatment for cystic fibrosis.

Authors:  N G McElvaney; R C Hubbard; P Birrer; M S Chernick; D B Caplan; M M Frank; R G Crystal
Journal:  Lancet       Date:  1991-02-16       Impact factor: 79.321

5.  Prolastin aerosol therapy and sputum taurine in cystic fibrosis.

Authors:  André M Cantin; Yves Berthiaume; Diane Cloutier; Marc Martel
Journal:  Clin Invest Med       Date:  2006-08       Impact factor: 0.825

6.  Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction.

Authors:  S D Sagel; R Kapsner; I Osberg; M K Sontag; F J Accurso
Journal:  Am J Respir Crit Care Med       Date:  2001-10-15       Impact factor: 21.405

7.  Elastin and collagen degradation products in urine of patients with cystic fibrosis.

Authors:  P J Stone; M W Konstan; M Berger; H L Dorkin; C Franzblau; G L Snider
Journal:  Am J Respir Crit Care Med       Date:  1995-07       Impact factor: 21.405

8.  High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis.

Authors:  Rabindra Tirouvanziam; Carol K Conrad; Teodoro Bottiglieri; Leonore A Herzenberg; Richard B Moss; Leonard A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

9.  Potential role of high-mobility group box 1 in cystic fibrosis airway disease.

Authors:  Steven M Rowe; Patricia L Jackson; Gang Liu; Mathew Hardison; Alessandra Livraghi; G Martin Solomon; D Brent McQuaid; Brett D Noerager; Amit Gaggar; J P Clancy; Wanda O'Neal; Eric J Sorscher; Edward Abraham; J Edwin Blalock
Journal:  Am J Respir Crit Care Med       Date:  2008-07-24       Impact factor: 21.405

10.  Sputum peroxidase activity correlates with the severity of lung disease in cystic fibrosis.

Authors:  W E Regelmann; C M Siefferman; J M Herron; G R Elliott; C C Clawson; B H Gray
Journal:  Pediatr Pulmonol       Date:  1995-01
View more
  89 in total

Review 1.  Building global development strategies for cf therapeutics during a transitional cftr modulator era.

Authors:  N Mayer-Hamblett; S van Koningsbruggen-Rietschel; D P Nichols; D R VanDevanter; J C Davies; T Lee; A G Durmowicz; F Ratjen; M W Konstan; K Pearson; S C Bell; J P Clancy; J L Taylor-Cousar; K De Boeck; S H Donaldson; D G Downey; P A Flume; P Drevinek; C H Goss; I Fajac; A S Magaret; B S Quon; S M Singleton; J M VanDalfsen; G Z Retsch-Bogart
Journal:  J Cyst Fibros       Date:  2020-06-07       Impact factor: 5.482

Review 2.  Mapping targetable inflammation and outcomes with cystic fibrosis biomarkers.

Authors:  Olivia Giddings; Charles R Esther
Journal:  Pediatr Pulmonol       Date:  2017-07-17

3.  The novel complex allele [A238V;F508del] of the CFTR gene: clinical phenotype and possible implications for cystic fibrosis etiological therapies.

Authors:  Anna Diana; Angela Maria Polizzi; Teresa Santostasi; Luigi Ratclif; Maria Giuseppina Pantaleo; Giuseppina Leonetti; Danila Rosa Iusco; Crescenzio Gallo; Massimo Conese; Antonio Manca
Journal:  J Hum Genet       Date:  2016-02-25       Impact factor: 3.172

4.  Neutrophil elastase correlates with increased sphingolipid content in cystic fibrosis sputum.

Authors:  Sophia Karandashova; Apparao Kummarapurugu; Shuo Zheng; Le Kang; Shumei Sun; Bruce K Rubin; Judith A Voynow
Journal:  Pediatr Pulmonol       Date:  2018-04-06

5.  Measurement of serum calprotectin in stable patients predicts exacerbation and lung function decline in cystic fibrosis.

Authors:  Philip A Reid; David A McAllister; A Christopher Boyd; J Alastair Innes; David Porteous; Andrew P Greening; Robert D Gray
Journal:  Am J Respir Crit Care Med       Date:  2015-01-15       Impact factor: 21.405

6.  Getting Our Fingers on the Pulse of Slow-Growing Bacteria in Hard-To-Reach Places.

Authors:  Tara Gallagher; Joann Phan; Katrine Whiteson
Journal:  J Bacteriol       Date:  2018-11-26       Impact factor: 3.490

7.  Sputum induction improves detection of pathogens in children with cystic fibrosis.

Authors:  Jordana E Hoppe; Elinor Towler; Brandie D Wagner; Frank J Accurso; Scott D Sagel; Edith T Zemanick
Journal:  Pediatr Pulmonol       Date:  2015-01-07

8.  2-O, 3-O-desulfated heparin inhibits neutrophil elastase-induced HMGB-1 secretion and airway inflammation.

Authors:  Kathryn L Griffin; Bernard M Fischer; Apparao B Kummarapurugu; Shuo Zheng; Thomas P Kennedy; Narayanam V Rao; W Michael Foster; Judith A Voynow
Journal:  Am J Respir Cell Mol Biol       Date:  2014-04       Impact factor: 6.914

9.  Molecular principles for heparin oligosaccharide-based inhibition of neutrophil elastase in cystic fibrosis.

Authors:  Apparao B Kummarapurugu; Daniel K Afosah; Nehru Viji Sankaranarayanan; Rahaman Navaz Gangji; Shuo Zheng; Thomas Kennedy; Bruce K Rubin; Judith A Voynow; Umesh R Desai
Journal:  J Biol Chem       Date:  2018-06-14       Impact factor: 5.157

Review 10.  Cystic Fibrosis: Microbiology and Host Response.

Authors:  Edith T Zemanick; Lucas R Hoffman
Journal:  Pediatr Clin North Am       Date:  2016-08       Impact factor: 3.278

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.